Intelligent Bio Solutions Inc. · NASDAQ:INBS
Intelligent Bio Solutions — Investor Presentation (August 2026)
25 slides from Intelligent Bio Solutions's investor presentation, August 2026
Slide 1: Pioneering Pain-free Solutions
Pioneering Pain-free Solutions Transforming drug testing with non-invasive, cost-effective, reliable solutions. NASDAQ: INBS | August 2026
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute “forward-looking INBS cautions that any forward-looking statements made by INBS are not statements” as defined in Section 27A of the Securities Act of 1933, as amended guarantees of future performance. Although INBS be
Slide 3: We are a medical technology company delivering intelligent, rapid, non-invasive testing
We are a medical technology company delivering intelligent, rapid, non-invasive testing solutions. Our mission is to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and improve the quality of life. NASDAQ: INBS 3
Slide 4: Simpler Drug Testing
Simpler Drug Testing Our Intelligent Fingerprinting Drug Screening System is revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. This efficient and cost-effective system is designed to screen for recent use of dr
Slide 5: 3 Steps to Simpler Drug Testing
3 Steps to Simpler Drug Testing 1 Donor places the tip of each finger on the fingerprint collection area for 5 seconds. 2 Test administrator inserts the cartridge into the digital reader. 3 The reader provides results in less than 10 minutes*. * INBS has commenced a Validation Study for a rapid drug
Slide 6: Our Advantage: Window of Detection
Our Advantage: Window of Detection Different drug testing sample types detect drug use over different time periods. Urine testing identifies drug use from several days or even weeks prior. Saliva testing detects drugs used up to 48 hours before testing. Fingerprint Drug Testing focuses on detecting
Slide 7: Consumables-led Recurring Revenue Model
Consumables-led Installed Readers in the Market Recurring 2000 1500 Revenue Model 1000 500 Drug Screening Reader 0 (1x sale) FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 Cartridge Sales 500,000 400,000 300,000 200,000 Disposable Drug 100,000 Screening Cartridge 0 (recurring revenue) FY 2021 FY 20
Slide 8: Full Year Revenue & Gross Margin
Full Year Revenue & Gross Margin Revenue ($M) for the Period Ending 30 June Gross Margin for the Period Ending 30 June $4.5 $4.21 65% $4.0 38% YoY $0.8 60% increase $3.5 $3.05 $3.0 $0.9 55% $0.6 $2.5 50% 48.6% $0.7 $2.0 $1.5 45% $2.5 $1.0 40.8% $1.8 40% $0.5 $- 35% FY 2025 FY 2026 FY 2025 FY 2026 Ca
Slide 9: Customer Accounts
Customer Accounts 500+ Active Accounts Sold into 35 Countries & Territories NASDAQ: INBS
Slide 10: Anticipated Milestones & Timing
Anticipated Milestones & Timing Timing Milestone Completion (Calendar Year) Clinical data collection across the Company’s FDA 510(k) clinical study program ✓ Aug 2026 Analysis, compilation and finalization of 510(k) submission package Ongoing Submission of package seeking FDA 510(k) clearance for th
Slide 11: Intelligent Fingerprinting Drug Testing
Intelligent Fingerprinting Drug Testing NASDAQ: INBS 11
Slide 12: How it Works
Consumption How it Works The journey of a drug through the body: Absorption: how the drug moves from the site of administration to the site of action. Distribution Distribution: the journey of the drug through the bloodstream to various tissues of the body. Metabolism: the process that breaks down t
Slide 13: Benefits of Fingerprint Drug Testing
Benefits of Fingerprint Drug Testing Reduce Risk Save Costs Increase Efficiency Aim to identify current Bring drug testing Rapidly collect samples impairment rather than past in-house and eliminate and employ batch testing use with a detection window the need for specialized to analyze drug screenin
Slide 14: Intelligent Fingerprinting vs Urine & Saliva Drug Testing
Intelligent Fingerprinting vs Urine & Saliva Drug Testing Fingerprint Saliva Urine Detection Window Up to 16 – 24 hours Up to 2 days Up to 4 days Less than 10 minutes Average Test Time Up to 20 minutes 20 minutes – 4 hours or more (2-3 mins when batch testing) Average Annual Cost * ~ $5,500 ~ $7,600
Slide 15: Market Opportunity
Market Opportunity Leveraging intelligent, non-invasive testing to address global demands. NASDAQ: INBS 15
Slide 16: FDA 510(k)
FDA-Related Work Completed Clinical cut-off study for codeine ✓ Multi-site method comparison ✓ FDA 510(k) Usability study ✓ In September 2025, the FDA determined that additional data was Interference study ✓ required from the Company, thus requiring it to submit a new 510(k) submission. Precision te
Slide 17: Addressing a $400 Billion Substance Abuse Problem
Addressing a $400 Billion Substance Abuse Problem1 The Drug Screening Market is projected to reach US$13.1 billion in 2026 and is expected to reach US$31 billion by 2032, growing at a CAGR of 15.4%2. Market Drivers • Workplace safety compliance in high-risk industries • Rising substance use concerns
Slide 18: U.S. Market Opportunity
U.S. Market Opportunity The U.S. Drug Screening Market was valued at US$4.6 billion in 2025, and is expected to reach US$9.4 billion by 20301. Market Drivers • Stringent federal and state regulations • Rising substance abuse concerns • Mandatory workplace testing requirements Opportunity • Strong pr
Slide 19: Target Sectors
Target Sectors Beyond Safety-Critical Workplace Settings Sports Government • Athlete testing (Professional, Collegiate and Schools) • Public safety and compliance initiatives • Border security and customs screening Aviation & Maritime • Workplace safety programs across state agencies • Flight and gr
Slide 20: Growing Drug Consumption
Growing Drug Consumption Approximately 331 million people used an illicit drug in 2024, a 34% increase over the last 10 years. 256 63 32 25 million million million million cannabis users, opioid users, amphetamine users, cocaine users, representing representing 4.8% of the representing 1.2% of the r
Slide 21: More Than 70% of Adults Abusing Alcohol or Illicit Drugs in the U.S. Are Employed
More Than 70% of Adults Abusing Alcohol or Illicit Drugs in the U.S. Are Employed1 Illicit drugs are a continuing issue, contributing to accidents in the workplace. In 2024, the combined U.S. workforce urine 1 Centers for Disease Control and Prevention, 2023. Mental Health, Alcohol Use, and Substanc
Slide 22: Drugs & Alcohol in the Workplace
Drugs & Alcohol in the Workplace Drug & Alcohol Testing per Industry 2021 Percentage of Establishments Testing New and Current Employees 1 Transportation and warehousing Retail trade Wholesale trade Manufacturing Construction Utilities 1 US Bureau of Labor Statistics, 2021. Business Response Survey
Slide 23: Capitalization Table
Securities Outstanding (as of June 30, 2026) Common Stock Issued 2,905,603 Capitalization Table Pre-funded Warrants 894,425 Total Common Equivalent Shares* 3,800,028 Warrants (WAEP - $6.51) 5,223,868 *No ratchets or resets. NASDAQ: INBS 23
Slide 24: Summary
Summary Large growing customer base with Rapid, non-invasive, cost-effective 1800+ installed readers and 500+ active solution to address the growing global customers. drug screening market. Strong Intellectual Property (IP) Increased revenue and growth, portfolio, including our sixth U.S. utilizing
Slide 25: Thank You
Thank You www.ibs.inc | info@ibs.inc NASDAQ: INBS 25
Intelligent Bio Solutions — Investor Presentation (August 2026) on 6ix